Brief: Argent Biopharma And Auscann Enters Strategic Heads Of Agreement
15/04/2025 02:29
April 15 (Reuters) - Argent BioPharma Ltd RGT.AX: CO, AUSCANN ENTERED STRATEGIC HEADS OF AGREEMENT TO ACCELERATE CANNABINOID-BASED PHARMACEUTICAL DEVELOPMENT AUSCANN WILL LICENSE ARGENT BIOPHARMA'S CANNEPIL CMC AND DOSSIER FOR NON-EPILEPSY RELATED PHARMACEUTICAL PROGRAMS Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program